203940-17-4

Upstream product

• 4965-33-7 2-methyl-7-chloroquinoline 
• 52178-50-4 Methyl 3-formylbenzoate 

Downstream Products

• 904916-27-4 {1-[1-{3-[(E)-2-(7-Chloro-quinolin-2-yl)-vinyl]-phenyl}-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethylsulfanylmethyl]-cyclopropyl}-acetic acid benzyl ester 
• 904916-32-1 [1-(2-(4-Chloro-benzenesulfonylamino)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-ethylsulfanylmethyl)-cyclopropyl]-acetic acid benzyl ester 
• 904916-33-2 (+/-)-methyl 4-{[(2-{4-chlorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}phenylacetate 
• 904916-34-3 (+/-)-methyl 4-{[(2-{4-chlorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]-2-ethyl}benzoate 
• 904916-37-6 (+/-)-methyl 4-{[(2-{4-nitrophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoate 
• 904916-29-6 (+/-)-methyl 4-{[(1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}-2-phthalimidoethyl)thio]-2-ethyl}benzoate 
• 904916-28-5 (+/-)-methyl 4-{[(1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}-2-phthalimidoethyl)thio]methyl}phenylacetate 
• 904916-38-7 (+/-)-methyl 4-{[(2-{4-fluorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoate 
• 203940-24-3 (+/-)-methyl 4-{[(1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}-2-phthalimidoethyl)thio]methyl}benzoate 
• 203940-25-4 (+/-)-methyl 4-{[(2-{4-chlorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoate 
• 904916-36-5 (+/-)-methyl 4-{[(2-{4-bromophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoate 
• 904916-31-0 (+/-)-methyl 4-[(2-{4-chlorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]-3,3-dimethylbutyrate 
• 904916-35-4 (+/-)-methyl 4-{[(2-{phenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoate 

Relevant academic research and scientific papers

PROCESS FOR AND INTERMEDIATES OF LEUKOTRIENE ANTAGONISTS

A process for synthesizing a β- ketoester of formula (VII) which comprises: (a) converting 3-methylbenzoic acid into alkyl 3-methylbenzoate; (b) reacting 3 -methyl benzoate to form alkyl 3 -bromomethylbenzoate; (c)converting alkyl 3-bromo methyl benzoate into alkyl 3-formylbenzoate; (d) condensing alkyl 3-formyl benzoate with 7- Chioroquinaldine to give alkyl 3- [((7-Chloro-2-quinolinyl) ethenyl)]benzoate; (e) hydrolyzing alkyl 3 -[((7-Chloro-2-quinolinyl)ethenyl) benzoate to give 3-[((7- Chloro- 2-quinolinyl)ethenyl)]benzoic acid; and (f) reacting 3-[((7-Chloro-2-quinolinyI) ethenyjbenzoic acid with a malonate to obtain a compound of structural formula VII.

A novel dual antagonist of thromboxane A2 and leukotriene D 4 receptors: Synthesis and structure-activity relationships of chloroquinolylvinyl derivatives

To discover an orally active thromboxane A2 (TXA2) and leukotriene D4 (LTD4) dual antagonist, we designed and synthesized chloroquinolylvinyl derivatives based on the structures of the TXA2 antagonist daltroban and the LTD4 antagonist montelukast. Among these derivatives, 4-{[(2-(4-chlorophenylsulfonylamino)-1-{3- [(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethyl)thio]methyl}benzoic acid (18d) showed potent inhibitory activity against U46619-induced aggregation of guinea pig platelets and LTD4-induced contraction in the guinea pig ileum, with IC50 values of 340 nm and 0.40 nm, respectively. Oral administration of 18 d also inhibited both the LTD4-induced acceleration of plasma leakage to skin in guinea pig and the U46619-induced increase in airway resistance in guinea pig with ED50 values of 0.47 mg/kg and 3.3 mg/kg, respectively.